Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit Read more about Iovance Biotherapeutics to Present at Chardan Genetic Medicines and Cell Therapy Manufacturing Summit
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma Read more about Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma
Iovance Biotherapeutics to Present at Upcoming Conferences Read more about Iovance Biotherapeutics to Present at Upcoming Conferences
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC) Read more about Iovance Biotherapeutics’ Investigational New Drug Application (IND) Allowed to Proceed for TALEN®-Edited Tumor Infiltrating Lymphocyte (TIL) in Unresectable or Metastatic Melanoma and Stage III or IV Non-Small Cell Lung Cancer (NSCLC)
Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting Read more about Iovance Biotherapeutics to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates Read more about Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Read more about Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022 Read more about Iovance Biotherapeutics to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast on Thursday, February 24, 2022